Last updated: August 17, 2026
Regadenoson, marketed primarily as Lexiscan, is a mature cardiovascular diagnostic drug used as a pharmacologic stress agent for radionuclide myocardial perfusion imaging. Its commercial profile is defined by established clinical adoption, low manufacturing complexity, loss of meaningful patent exclusivity, and increasing generic competition. Standalone Lexiscan revenue is not separately disclosed in current public financial reporting, limiting precise product-level revenue modeling.
What is regadenoson and how is Lexiscan used?
Regadenoson is a selective adenosine A2A receptor agonist administered intravenously before radionuclide myocardial perfusion imaging. The approved product is a 0.4 mg/5 mL single-dose injection.
The FDA approved Lexiscan on April 10, 2008, for use in adults who cannot achieve adequate exercise stress during myocardial perfusion imaging.[1] Regadenoson produces coronary vasodilation and increases myocardial blood flow, allowing imaging laboratories to assess perfusion without exercise or continuous adenosine infusion.
How does regadenoson compare with adenosine?
| Attribute |
Regadenoson |
Adenosine |
| Primary receptor profile |
Selective A2A agonist |
Nonselective adenosine agonist |
| Administration |
Single rapid IV bolus |
Continuous IV infusion |
| Standard commercial dose |
0.4 mg |
Weight- and protocol-dependent |
| Typical imaging use |
Pharmacologic myocardial perfusion imaging |
Pharmacologic myocardial perfusion imaging |
| Operational burden |
Lower |
Higher |
| Generic substitution risk |
High |
High |
| Clinical differentiation |
Simpler administration and protocol integration |
Longer clinical history and lower-cost alternatives |
Regadenoson’s principal commercial advantage is operational. A fixed-dose bolus is easier to administer than an adenosine infusion. That advantage supported adoption in hospitals and outpatient imaging centers, but it does not create a durable barrier once generic regadenoson is available.
What is the FDA regulatory status of Lexiscan?
Lexiscan is an FDA-approved small-molecule injectable drug. It is not a biologic and does not require a biosimilar pathway.
| Regulatory event |
Date or status |
| FDA approval |
April 10, 2008 |
| Active ingredient |
Regadenoson |
| Dosage form |
Intravenous injection |
| Approved use |
Pharmacologic stress for radionuclide myocardial perfusion imaging |
| Regulatory pathway for competitors |
Abbreviated New Drug Application |
| Pediatric exclusivity |
No material current exclusivity identified in public product materials |
| Current market status |
Mature branded product with generic competition |
The commercial market is governed primarily by ANDA approvals, state substitution rules, hospital formulary decisions, group purchasing organization contracts, and acquisition cost. No new biologics-license application or biosimilar framework applies.
What patents protect regadenoson and Lexiscan?
The core regadenoson patent estate was built around adenosine A2A receptor agonists. U.S. Patent No. 6,528,491, assigned to CV Therapeutics, covered relevant compounds and uses and issued in 2003.[2] The patent reached the end of its ordinary U.S. term in the early 2020s after accounting for applicable patent-term adjustments and extensions.
Patent position
| Patent issue |
Commercial implication |
| Core compound patent |
No longer provides a durable U.S. monopoly |
| Product formulation |
Limited ability to block standard injectable copies |
| Method-of-use claims |
Narrower protection tied to imaging or patient populations |
| Manufacturing claims |
Potential process protection, but usually not a broad barrier to ANDA entry |
| Patent-term status |
Core protection has expired or is no longer sufficient to prevent routine generic entry |
The Orange Book remains the relevant FDA source for listed patents and regulatory exclusivities.[3] A patent listing does not necessarily prevent approval of an ANDA. A generic applicant can file a Paragraph IV certification challenging listed patents, or it can wait for the relevant patent term to expire.
When did regadenoson lose exclusivity?
Regadenoson lost practical market exclusivity after the expiration of the original compound and use-patent protections. FDA approval occurred in 2008, but the key patent estate dates from earlier CV Therapeutics research and filings.
The exclusivity timeline is:
| Period |
Market position |
| 2008-2010 |
Lexiscan established as a new pharmacologic stress agent |
| 2010s |
Branded product retained commercial leadership through clinical adoption and distribution |
| Early 2020s |
Core U.S. patent protection ceased to provide a meaningful barrier |
| 2023 onward |
Generic ANDA competition expanded |
| Current market |
Brand and generic products compete primarily on price, supply, and contracting |
The loss of exclusivity did not eliminate Lexiscan revenue immediately. Diagnostic centers often maintain branded products because of historical protocols, inventory systems, physician familiarity, and contractual arrangements. The erosion is gradual, but generic substitution places direct pressure on price and volume.
Which companies are challenging Lexiscan through generic competition?
Generic regadenoson products have entered the U.S. market through ANDA approvals and commercial launches by multiple manufacturers. Public FDA product databases and labeling repositories identify generic regadenoson injection products from manufacturers including Teva and other injectable-drug suppliers.[4][5]
The competitive field is likely to remain fragmented because regadenoson is a relatively simple sterile injectable with limited differentiation. The most important competitive factors are:
- FDA approval and manufacturing compliance.
- Reliable sterile-injectable supply.
- Hospital and group purchasing organization contracts.
- Wholesale acquisition cost and net contract price.
- Ability to maintain inventory during injectable-drug shortages.
A generic applicant does not need to reproduce Lexiscan’s brand infrastructure. It must demonstrate pharmaceutical equivalence and bioequivalence, comply with current good manufacturing practices, and meet FDA quality requirements.
What Paragraph IV risks affected Lexiscan?
Paragraph IV risk was most relevant before expiration of the principal listed patents. Generic applicants could certify that listed patents were invalid, unenforceable, or not infringed. If the brand owner filed a timely infringement action, FDA approval could be subject to a statutory 30-month stay.
For a mature product such as regadenoson, the current commercial issue is less about future Paragraph IV litigation and more about the number of approved ANDAs, launch timing, and contracting behavior. Once the key patents expired, the legal basis for blocking standard generic entry weakened substantially.
What formulation patents protect regadenoson injection?
The commercial Lexiscan product uses a conventional sterile aqueous injectable formulation. That reduces the likelihood that formulation patents can preserve broad product exclusivity after the core compound patent expires.
Potential formulation or manufacturing claims may cover:
- Concentration and excipient composition.
- Sterility and container closure systems.
- Stability during storage.
- Filling and packaging processes.
- Specific administration protocols.
These claims can create narrow litigation risk, but they do not necessarily prevent an ANDA applicant from using a different formulation or manufacturing process. The absence of a complex delivery device, depot formulation, or biologic production process limits the strength of formulation-based barriers.
How strong is the regadenoson patent estate?
The current patent estate is weak as a barrier to U.S. generic entry.
| Patent-strength factor |
Assessment |
| Core molecule protection |
Expired or commercially exhausted |
| New chemical entity exclusivity |
Expired |
| Delivery-system complexity |
Low |
| Manufacturing complexity |
Moderate because the product is sterile injectable |
| Formulation differentiation |
Limited |
| Method-of-use protection |
Narrow and difficult to use as a broad market barrier |
| Biosimilar protection |
Not applicable |
| Litigation leverage |
Low relative to protected specialty drugs |
The strongest remaining barrier is manufacturing execution, not intellectual property. Sterile injectable production requires validated facilities, quality systems, inspection readiness, and dependable supply chains. That barrier can delay or constrain entry, but it does not support premium pricing in the way a live composition-of-matter patent does.
What is the Orange Book status of Lexiscan?
Lexiscan is an FDA-listed prescription drug, and the Orange Book is the authoritative source for its approved products, therapeutic-equivalence evaluations, patent listings, and exclusivity information.[3]
The practical Orange Book implications are:
- Lexiscan has an approved reference listed drug designation.
- Generic regadenoson products can rely on the reference product through the ANDA pathway.
- Expired core patents do not support continued market exclusivity.
- Any remaining listed patents must be evaluated claim by claim.
- The presence of a listed patent does not prove that a generic launch is blocked.
Therapeutic-equivalence ratings and product-specific approval status should be assessed in the current Orange Book rather than inferred from historical litigation.
Who owns and markets Lexiscan?
Lexiscan originated with CV Therapeutics. Gilead Sciences acquired CV Therapeutics in 2009, bringing the product into Gilead’s portfolio.[6] U.S. commercialization has been associated with Astellas under a licensing and commercial arrangement, while Gilead retained economic rights under the relevant agreements.[7]
The ownership and commercialization history is important because it explains why product economics have not always appeared as a standalone line item in a single company’s reported revenue.
Licensing and commercial structure
| Company |
Historical role |
| CV Therapeutics |
Original developer |
| Gilead Sciences |
Acquired CV Therapeutics and its assets |
| Astellas |
U.S. commercialization and distribution role |
| Generic manufacturers |
ANDA-based competitors after patent barriers weakened |
License terms, royalty rates, minimum payments, and product-specific net sales are not fully disclosed in current public filings. The commercial structure makes it difficult to calculate exact manufacturer-level margins from reported statements.
What is the financial trajectory for regadenoson?
Regadenoson is a mature, cash-generating diagnostic product rather than a growth asset. Its financial trajectory has four stages:
Launch and adoption
Lexiscan gained adoption because it simplified pharmacologic stress testing. Its fixed-dose bolus reduced operational complexity compared with adenosine infusion. The product benefited from the scale of nuclear cardiology and the recurring need for myocardial perfusion imaging.
Mature branded revenue
During the 2010s, Lexiscan remained an established product in the U.S. market. Revenue was supported by physician familiarity, hospital protocols, and the difficulty of rapidly changing entrenched imaging workflows.
Patent erosion
As core patent protection expired, the economic value of brand ownership declined. The product moved from an exclusivity-driven model to a contracting-driven model. Discounts, rebates, and generic substitution became more important than list price.
Generic decline
Generic entry creates three forms of pressure:
- Lower average selling price.
- Reduced brand share in hospital accounts.
- Higher customer leverage during contract negotiations.
Brand revenue can persist where physicians or institutions prefer the reference product, but the long-term direction is downward unless the brand retains a meaningful supply, service, or contracting advantage.
Financial disclosure limitations
Gilead and Astellas do not consistently disclose Lexiscan revenue as a separate current reporting segment. Product-level revenue, gross margin, royalty income, and U.S. net sales therefore cannot be reliably reconstructed from consolidated filings alone.[6][7]
The appropriate investment interpretation is that regadenoson has residual value as a mature royalty or branded injectable asset, but limited capacity for material revenue growth. The asset’s value is more sensitive to generic penetration, net pricing, supply reliability, and royalty structure than to market expansion.
What generic launch scenarios exist for regadenoson?
| Scenario |
Likely effect |
| One or two generic suppliers |
Moderate price erosion; brand may retain meaningful share |
| Several reliable suppliers |
Faster conversion of hospitals and imaging centers |
| Aggressive GPO contracting |
Significant net-price reduction |
| Sterile-injectable supply disruption |
Temporary brand or incumbent-supplier share recovery |
| Hospital preference for reference product |
Slower substitution |
| Broad shortage affecting all suppliers |
Volume volatility and increased procurement risk |
The most probable long-term scenario is continued generic penetration with declining branded share. Regadenoson’s market will not behave like a specialty drug market because the clinical indication is established, the product is chemically simple, and prescribers generally have limited incentive to avoid therapeutically equivalent generics.
What revenue exposure and market risks matter most?
The principal risks are commercial rather than scientific:
- Generic price compression.
- Loss of hospital formulary preference.
- Dependence on sterile injectable manufacturing.
- Reduced royalty income for legacy rights holders.
- Contract concentration among wholesalers and GPOs.
- Potential supply interruptions.
- Declining nuclear cardiology procedure volumes.
- Competition from alternative stress agents, including adenosine and other pharmacologic options.
The principal support factors are:
- Established clinical protocols.
- Large installed base of nuclear imaging equipment.
- Simple administration.
- Recurring use in patients unable to exercise adequately.
- Switching friction in hospital procurement systems.
- Limited need for physician retraining.
Geographic protection is limited. U.S. economics are the most commercially visible because of Lexiscan’s origin and market penetration. Patent expiry and generic entry must be evaluated separately by jurisdiction, since national patent terms, regulatory approvals, and reimbursement systems differ.
Key Takeaways
- Regadenoson is a mature pharmacologic stress agent marketed primarily as Lexiscan.
- FDA approval was granted in 2008 for radionuclide myocardial perfusion imaging.
- Its main clinical advantage is single-bolus administration rather than continuous adenosine infusion.
- Core U.S. patent protection has expired or no longer provides a meaningful barrier to routine generic entry.
- The product is subject to ANDA competition, not biosimilar competition.
- Sterile injectable manufacturing is the main remaining entry barrier.
- Brand revenue is expected to decline through lower pricing and generic substitution.
- Current public filings do not provide a dependable standalone Lexiscan revenue series.
- The asset retains residual commercial value but has limited growth potential.
FAQs
Is regadenoson still under patent protection?
The principal U.S. composition and use protections associated with the original regadenoson program are no longer an effective broad barrier to generic competition. Any remaining patent issue must be checked against the current FDA Orange Book and applicable jurisdiction.
Is Lexiscan interchangeable with generic regadenoson?
FDA-approved generic regadenoson injection products may receive therapeutic-equivalence ratings that support substitution, subject to the specific product listing and state pharmacy law. Hospital purchasing decisions can still differ from retail substitution rules.
Does regadenoson have biosimilar competition?
No. Regadenoson is a chemically synthesized small molecule. Competitors use the ANDA generic-drug pathway rather than the biosimilar pathway.
What is the main manufacturing risk for generic regadenoson?
The principal risk is sterile injectable production. Facility qualification, sterility assurance, inspection compliance, and supply continuity can be more difficult than the active ingredient chemistry.
Can Lexiscan revenue recover after generic entry?
A sustained recovery is unlikely without a supply disruption, a new approved indication, or a commercial strategy that preserves reference-product preference. The normal trajectory after generic entry is lower price and declining branded share.
References
- U.S. Food and Drug Administration. (2008). Lexiscan (regadenoson) injection prescribing information.
- U.S. Patent and Trademark Office. (2003). U.S. Patent No. 6,528,491: Adenosine A2A receptor agonists.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database.
- National Library of Medicine. (n.d.). DailyMed: Regadenoson injection labeling.
- Gilead Sciences, Inc. (2010). Annual report.
- Astellas Pharma Inc. (2024). Annual report and financial results materials.
